» Articles » PMID: 22246969

Single Versus Multiple Primary Melanomas: Old Questions and New Answers

Overview
Journal Cancer
Publisher Wiley
Specialty Oncology
Date 2012 Jan 17
PMID 22246969
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In patients with multiple primary melanomas (MPM), mean tumor thickness tends to decrease from the first melanoma to the second melanoma, and prognosis may be improved compared with the prognosis for patients who have a single primary melanoma (SPM). In this study, the authors compared the clinicopathologic features of patients with MPM and SPM to better characterize the differences between these 2 groups and to determine whether or not there is an inherent difference in tumor aggression.

Methods: In total, 788 patients with melanoma who were enrolled prospectively in the Interdisciplinary Melanoma Cooperative Group database from 2002 to 2008 were studied. Patients with SPM and with MPM were compared with regard to clinical and primary melanoma characteristics.

Results: Of 788 patients with melanoma, 61 patients (7.7%) had 2 or more primary melanomas. The incidence of developing a second primary melanoma 1 year and 5 years after initial melanoma diagnosis was 4.1% and 8.7%, respectively, and most of the risk accumulated within the first year. The incidence of MPM was greater in patients aged ≥60 years than in those aged ≤60 years. The absence or presence of mitosis and other tumor characteristics did not differ significantly between patients with SPM and patients with MPM (P = .61).

Conclusions: No difference was observed in the presence or absence of mitoses, a marker of tumor proliferation, in SPM and MPM. Because it has been demonstrated that the presence of mitosis is a powerful prognostic marker, the current findings suggested that the tumors behave similarly in patients with SPM and patients with MPM. The authors concluded that differences in tumor thickness and prognosis between SPM and MPM more likely are caused by factors other than tumor biology, such as increased surveillance.

Citing Articles

Multiple Primary Melanomas: Retrospective Review in a Tertiary Care Hospital.

Palacios-Diaz R, de Unamuno-Bustos B, Abril-Perez C, Pozuelo-Ruiz M, Sanchez-Arraez J, Torres-Navarro I J Clin Med. 2022; 11(9).

PMID: 35566480 PMC: 9105033. DOI: 10.3390/jcm11092355.


Incidence of Second Primary Melanoma in Cutaneous Melanoma Survivors.

Wiener A, Schumacher J, Racz J, Weber S, Xu Y, Neuman H Ann Surg Oncol. 2022; 29(9):5925-5932.

PMID: 35505144 PMC: 11898002. DOI: 10.1245/s10434-022-11725-8.


Poorer survival outcomes in patients with multiple versus single primary melanoma.

Karapetyan L, Yang X, Knight A, Huang Z, Wang H, Sander C Cancer. 2022; 128(11):2098-2106.

PMID: 35319783 PMC: 11072316. DOI: 10.1002/cncr.34169.


Fortuitous discovery of melanomas in the ENT Department - a histopathological and immunohistochemical study.

Trandafir C, Tischer A, Horhat I, Balica N, Sitaru A, Guran K Rom J Morphol Embryol. 2021; 61(4):1163-1171.

PMID: 34171065 PMC: 8343656. DOI: 10.47162/RJME.61.4.18.


Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis.

Dika E, Broseghini E, Porcellini E, Lambertini M, Riefolo M, Durante G Cell Death Dis. 2021; 12(5):473.

PMID: 33980826 PMC: 8115306. DOI: 10.1038/s41419-021-03764-y.